PatientID: HDR79

Okitobba 06, 2023

Color Code

HR: High-Level Resistance
LR: Low-Level Resistance
IR: Intermediate Resistance

S: Susceptible

DRUG.CLASS	DRUG	RESISTANCE.PROFILE	DRMS.above.20.percent.prevalence
PI	ATV	S	
	DRV	\mathbf{S}	
	FPV	\mathbf{S}	
	IDV	\mathbf{S}	
	LPV	${f S}$	
	NFV	S	
	SQV	\mathbf{S}	
	TPV	\mathbf{S}	
NRTI	ABC	IR	
	AZT	$_{ m HR}$	
	D4T	IR	
	DDI	IR	M184V;T215F;K219R
	FTC	$_{ m HR}$	
	LMV	$_{ m HR}$	
	TDF	${f S}$	
NNRTI	DOR	$_{ m LR}$	
	EFV	$_{ m HR}$	
	ETR	IR	K101E;G190A
	NVP	$_{ m HR}$	
	RPV	$_{ m HR}$	
INSTI	BIC	\mathbf{S}	
	CAB	\mathbf{S}	
	DTG	\mathbf{S}	
	EVG	\mathbf{S}	
	RAL	${f S}$	

Appendix

Drug abbreviations in full

DRUG.CLASS	ABBREVIATION	DRUG.NAME
	ATV	Atazanavir
	DRV	Darunavir
	FPV	Fosamprenavir
PI	IDV	Indinavir
11	LPV	Lopinavir
	NFV	Nelfinavir
	SQV	Saquinavir
	TPV	Tipranavir
	ABC	Abacavir
	AZT	Azidothymidine
	DFT	Stavudine
NRTI	DDI	Didanosine
	FTC	Emtricitabine
	LMV	Lamivudine
	TDF	Tenofovir
	DOR	Doravirine
	EFV	Efavirenz
NNRTI	ETR	Etravirine
	NVP	Nevirapine
	RPV	Rilpivirine
	BIC	Bictegravir
	CAB	Cabotegravir
INSTI	DTG	Dolutegravir
	EVG	Elvitegravir
	RAL	Raltegravir

Comments

DRUG.CLASS	COMMENTS
PI	
	K219E/Q/N/R are accessory TAMS that usually occur in combination with multiple other
	TAMs.
	M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate
	resistance to ABC (3-fold reduced susceptibility). M184V/I are not contraindications to
NRTI	continued treatment with 3TC or FTC because they increase susceptibility to AZT and
	TDF and are associated with clinically significant reductions in HIV-1 replication.
	T215Y/F are TAMs that causes intermediate/high-level resistance to AZT and potentially
	low-level resistance to ABC and TDF.
NNRTI	G190A is a non-polymorphic mutation that causes high-level resistance to NVP and
	intermediate resistance to EFV. It does not significantly reduce susceptibility to RPV,
	ETR, or DOR.
	K101E is a non-polymorphic accessory mutation that confers intermediate resistance to
	NVP and RPV and low-level reductions in susceptibility to EFV, ETR, and DOR when it
	occurs with other NNRTI-resistance mutations.
INSTI	